UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 7, 2010
K-V Pharmaceutical Company
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 1-9601 | 43-0618919 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| One Corporate Woods Drive Bridgeton, MO |
63044 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (314) 645-6600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
As previously disclosed in prior filings, K-V Pharmaceutical Company (the “Company”) has been pursuing the sale of certain of its assets as part of an ongoing effort to manage and increase its cash. In connection therewith, on May 7, 2010, the Company received $11 million in cash proceeds, and a right to receive an additional payment of $2 million based on the occurrence of certain events, from the sale of certain intellectual property and other assets related to the Company’s Abbreviated New Drug Application, submitted with the U.S. Food and Drug Administration for the approval to engage in the commercial manufacture and sale of 1gm/10mL sucralfate suspension.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| K-V Pharmaceutical Company | ||
| By: | /s/ David A. Van Vliet | |
| David A. Van Vliet | ||
| Interim President and Interim Chief Executive Officer | ||
| Date: May 12, 2010 | ||